Bioavailability of Chlorogenic and Phenolic Acids From Soluble Coffees

NCT ID: NCT01400386

Last Updated: 2014-05-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 14 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-11-30
• Study Completion Date: 2013-06-30

Brief Summary

Coffee contributes to a large extent to our daily intake of phenolic compounds which have been associated with potential health benefits. A study by Richelle et al. (2001), using an LDL oxidation assay, showed that phenolic compounds in coffee possessed antioxidant activity which varied depending on the coffee bean source and the degree of roasting. Little is known about the bioavailability of phenolic compounds from coffee at various roasting degrees. Therefore, further human studies are required in order to demonstrate the absorption, and bioavailability of metabolites that may also be efficient in vivo.

The main objective of this clinical trial is to investigate the possible difference in the bioavailability of chlorogenic and phenolic acids from coffee at various roasting levels.

Detailed Description

Coffee contributes to a large extent to our daily intake of phenolic compounds which have been associated with potential health benefits. A study by Richelle et al. (2001), using an LDL oxidation assay, showed that phenolic compounds in coffee possessed antioxidant activity which varied depending on the coffee bean source and the degree of roasting. Little is known about the bioavailability of phenolic compounds from coffee at various roast levels. Therefore, further human studies are required in order to demonstrate the absorption, and bioavailability of metabolites that may also be efficient in vivo.

The main objective of this clinical trial is to investigate the possible difference in the bioavailability of chlorogenic and phenolic acids from coffee at different roast levels.

After medical examination and approval, subjects will be randomly assigned to one of the four coffee treatments. Each study period correspond to the ingestion of one the treatments and study periods are separated by a one week washout period. Blood will be taken as a time course for 24h while urine will be collected for 30h. Investigators are also blinded with respect to the dose and the treatment given to the subjects.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: QUADRUPLE

Study Groups

Soluble coffee 1

Group Type: EXPERIMENTAL

Coffee bioavailability trial

Intervention Type: OTHER

Coffee bioavailability trial

Soluble coffee 2

Group Type: EXPERIMENTAL

Coffee bioavailability trial

Intervention Type: OTHER

Coffee bioavailability trial

Soluble coffee 3

Group Type: EXPERIMENTAL

Coffee bioavailability trial

Intervention Type: OTHER

Coffee bioavailability trial

Soluble coffee 4

Group Type: EXPERIMENTAL

Coffee bioavailability trial

Intervention Type: OTHER

Coffee bioavailability trial

Interventions

Coffee bioavailability trial

Coffee bioavailability trial

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• 20 - 60 years, male and female
• healthy as determined by the medical questionnaire and the medical visit
• normal weight: BMI 19 - 25
• Coffee drinkers with an average consumption of 2-5 cups per day
• having given informed consent

Exclusion Criteria

• Intestinal or metabolic diseases / disorders such as diabetic, renal, hepatic, hypertension, pancreatic or ulcer
• food allergy
• Have had a major gastrointestinal surgery
• Difficulty to swallow
• Have a regular consumption of medication
• Have taken antibiotic therapy within the last 6 months
• Alcohol consumption > 2 units a day
• Smokers > 5 cigarettes a day
• Have given blood within the last 3 weeks before the start of the study
• Volunteers who cannot be expected to comply with treatment
• Currently participating or having participated in another clinical trial during the last 3 weeks

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Société des Produits Nestlé (SPN)

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Maurice Beaumont, MD, Ph.D

Role: PRINCIPAL_INVESTIGATOR

Société des Produits Nestlé (SPN)

Locations

NESTEC/Clinical Development Unit / Metabolic Unit

Lausanne, Canton of Vaud, Switzerland

Countries

Switzerland

Other Identifiers

10.04.Met

Identifier Type: -

Identifier Source: org_study_id